Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis

Cancer Research

Volumn 62, Issue 3, 2002, Pages 789-795

  Reimer, Corinne L ^a   Agata, Naoki ^a   Tammam, Jennifer G ^a   Bamberg, Michael ^a   Dickerson, William M ^a   Kamphaus, George D ^a   Rook, Susan L ^a   Milhollen, Michael ^a   Fram, Robert ^a   Kalluri, Raghu ^a   Kufe, Donald ^b   Kharbanda, Surender ^c  

^a Protein Division   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLUOROURACIL; ISOCOUMARIN DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; BREAST NEOPLASMS; CELL MOVEMENT; COUMARINS; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROURACIL; GROWTH INHIBITORS; HUMANS; ISOCOUMARINS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036468565     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. What is the evidence that tumors are angiogenesis dependent?
2. Angiogenesis inhibitors generated by tumors
3. Clinical applications of angiogenic growth factors and their inhibitors
4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses turnout growth in vivo
5. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
6. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
7. Antiangiogenic agents
8. Antiangiogenic turnout therapy: Will it work?
9. Angiogenesis: Regulators and clinical applications
10. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
11. Antiintegrin α v β 3 blocks human breast cancer growth and angiogenesis in human skin
12. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
13. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents
14. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts
15. Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth
16. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
17. Fibrosis and angiogenesis
18. Supramolecular assembly of basement membranes
19. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin
20. Distinct antitumor properties of a type IV collagen domain derived from basement membrane
21. Two RGD-independent alpha vβ 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
22. Combined effects of angiostatin and ionizing radiation in antitumour therapy
23. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity
24. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
25. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment
26. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo
27. Inhibition of angiogenesis by a new isocoumarin, NM-3
28. NM-3, a novel orally bioavailable antiangiogenic agent, suppresses hypoxia-induced vascular endothelial growth factor (VEGF) in human fibroblasts and tumor cells
29. NM-3, a novel angiogenesis inhibitor, inhibits tumor growth alone and in combination with cyclophosphamide
30. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
31. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents
32. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
33. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity